Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Immune Checkpoint Inhibitors & Ovarian Cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Although numerous trials have been undertaken, only scanty results have been obtained so far with Immune checkpoint inhibitors (ICIs) in Ovarian Cancer either when used as single agents or in combination with antiangiogenic therapy and ongoing trials are exploring the association of ICIs with PARPis and other ICIs.
Lorusso et al. 2020 Expert Opinion on Emerging Drugs 25: 445-453

…

References (Sources)

Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer
Lee & Konstantinopoulos 2019 Trends in Cancer 5: 524
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer
Lorusso et al. 2020 Expert Opinion on Emerging Drugs 25: 445-453
Review
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
Pawłowska et al. 2019 Clin Exp Immunol 195(3): 334-344
Review
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft et al. 2019 JCO 37: 2460–2471
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Immune Checkpoint Inhibitors & Ovarian Cancer

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat